277 related articles for article (PubMed ID: 31276898)
1. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
2. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
3. G9a - An Appealing Antineoplastic Target.
Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells.
Zhang J; Yao D; Jiang Y; Huang J; Yang S; Wang J
Bioorg Chem; 2017 Jun; 72():168-181. PubMed ID: 28460359
[TBL] [Abstract][Full Text] [Related]
5. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681949
[TBL] [Abstract][Full Text] [Related]
6. Depletion of G9a gene induces cell apoptosis in human gastric carcinoma.
Lin X; Huang Y; Zou Y; Chen X; Ma X
Oncol Rep; 2016 May; 35(5):3041-9. PubMed ID: 27081761
[TBL] [Abstract][Full Text] [Related]
7. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.
Irifuku T; Doi S; Sasaki K; Doi T; Nakashima A; Ueno T; Yamada K; Arihiro K; Kohno N; Masaki T
Kidney Int; 2016 Jan; 89(1):147-57. PubMed ID: 26444031
[TBL] [Abstract][Full Text] [Related]
10. Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Rahman Z; Bazaz MR; Devabattula G; Khan MA; Godugu C
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22674. PubMed ID: 33283949
[TBL] [Abstract][Full Text] [Related]
11. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
Agarwal P; Jackson SP
Cancer Lett; 2016 Oct; 380(2):467-475. PubMed ID: 27431310
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
Lenstra DC; Al Temimi AHK; Mecinović J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
[TBL] [Abstract][Full Text] [Related]
14. Histone Methyltransferase G9a Regulates Expression of Nuclear Receptors and Cytochrome P450 Enzymes in HepaRG Cells at Basal Level and in Fatty Acid Induced Steatosis.
Pande P; Zhong XB; Ku WW
Drug Metab Dispos; 2020 Dec; 48(12):1321-1329. PubMed ID: 33077425
[TBL] [Abstract][Full Text] [Related]
15. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; Roa S; Paiva B; Estella-Hermoso de Mendoza A; Alvarez RM; Casares N; Segura V; Martín-Subero JI; Ogi FX; Soule P; Santiveri CM; Campos-Olivas R; Castellano G; de Barrena MGF; Rodriguez-Madoz JR; García-Barchino MJ; Lasarte JJ; Avila MA; Martinez-Climent JA; Oyarzabal J; Prosper F
Nat Commun; 2017 May; 8():15424. PubMed ID: 28548080
[TBL] [Abstract][Full Text] [Related]
16. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
[TBL] [Abstract][Full Text] [Related]
18. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
